Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a254450bbc146c75

Jump to content

Cost-minimization analysis

From Wikipedia, the free encyclopedia

Cost-minimization is a tool used in pharmacoeconomics to compare the cost per course of treatment when alternative therapies have demonstrably equivalent clinical effectiveness.[1][2][3]

Therapeutic equivalence (including adverse reactions, complications and duration of therapy) must be referenced by the author conducting the study and should have been done prior to the cost-minimization work. Since equal efficacy and equal tolerability is already demonstrated, there is no requirement to find a common efficacy denominator as would be the case when conducting a cost-effectiveness study. The author is not precluded from doing so through the use of "cost/cure" or "cost/year of life gained". If efficacy and tolerability is demonstrated, however, then a simple comparison of "cost/course of treatment" can suffice for the purpose of comparing two or more therapeutically equivalent treatment alternatives. When conducting a cost-minimization study, the author needs to measure all costs (resource expenditures) inherent to the delivery of the therapeutic intervention and that are relevant to the pharmacoeconomic perspective. The optimal choice is that which can be provided for the lowest cost.[citation needed]

References

[edit]
  1. Suchmacher, Mendel; Geller, Mauro (2021). "Pharmacoeconomics". Practical Biostatistics. pp. 29–44. doi:10.1016/B978-0-323-90102-4.00019-9. ISBN 978-0-323-90102-4.
  2. Darst, Marc A.; Reddan, Jennifer; Feneran, Ashley N. (2013). "Pharmacoeconomics". Comprehensive Dermatologic Drug Therapy. pp. 757–765.e1. doi:10.1016/B978-1-4377-2003-7.00067-4. ISBN 978-1-4377-2003-7.
  3. Brown, Gary C.; Brown, Melissa M. (2010). "Value-based medicine and pharmacoeconomics". Retinal Pharmacotherapy. pp. 356–361. doi:10.1016/B978-1-4377-0603-1.00057-0. ISBN 978-1-4377-0603-1.